Creating a smart nanotherapy for cancers resistant to EGFR treatments
Development of a smart transformable nanotherapeutic against cancers with acquired resistance to EGFR-targeted therapies caused by MET amplification
This study is testing a new treatment that uses tiny particles to help fight certain cancers, like breast and colorectal cancer, that have stopped responding to current therapies, by targeting two specific proteins at once to improve effectiveness and reduce side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Khon Kaen University NIH-funded |
| Lab location | 1 site (Khon Kaen, Thailand) |
| Project ID | NIH-10978322 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanotherapeutic that can adapt and target cancers that have become resistant to existing EGFR-targeted therapies due to MET amplification. By utilizing a peptide-based platform, the approach aims to simultaneously target both EGFR and MET receptors, potentially overcoming the challenges posed by drug resistance. Patients with specific types of cancer, such as breast and colorectal cancer, may benefit from this innovative treatment strategy. The research involves advanced nanotechnology and targeted drug delivery methods to enhance treatment efficacy while minimizing side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers, particularly breast and colorectal cancers, that have shown resistance to EGFR-targeted therapies.
Not a fit: Patients whose cancers are not associated with EGFR or MET pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with cancers that have developed resistance to current therapies, improving their chances of recovery.
How similar studies have performed: While the approach of using nanotherapeutics is gaining traction, this specific strategy of co-targeting EGFR and MET in the context of drug resistance is relatively novel and has not been extensively tested.
Where this research is happening
Khon Kaen, Thailand
- Khon Kaen University — Khon Kaen, Thailand (Active)
Researchers
- Principal investigator: Mahalapbutr, Panupong — Khon Kaen University
- Study coordinator: Mahalapbutr, Panupong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.